Search | Clinical Trials Finder

Conditions: MDD
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Cerritos, California • Costa Mesa, California • Garden Grove, California + 21 more

Conditions: Chronic Medical Conditions, Depression
Interventions: FACE-PC; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Bryant, Arkansas • Chino, California • Fresno, California + 16 more

Conditions: Depressive Symptoms
Interventions: Computerized Cognitive Training, Control; Other
Lead sponsor: Queens College, The City University of New York; Other
Eligibility: 18 Years to 29 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions: SPT-300; Drug
Lead sponsor: Seaport Therapeutics; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Chino, California • Garden Grove, California • Glendale, California + 16 more

Conditions: Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Costa Mesa, California • Culver City, California • Glendale, California + 22 more

Conditions: Major Depressive Disorder
Interventions: ALTO-100 PO Tablet; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Coral Gables, Florida • Jackson, Mississippi

Conditions: Cognitive/Functional Effects, Depression, Hematopoietic/Lymphoid Cancer, Malnutrition, Pain, Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes
Interventions: medical chart review, questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more

Conditions: Alcoholism, Depression
Interventions: NALTREXONE, Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 55 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: NG-nitro-L-arginine methyl ester (L-NAME); Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Treatment of Depression in Adults With Parkinson's Disease (PD)
Interventions: Pimavanserin; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 21
States / cities: Costa Mesa, California • Fountain Valley, California • Pasadena, California + 18 more

Conditions: Depression, Depression in Old Age, Elder Abuse, Anxiety
Interventions: PROTECT with Technology Augmentation; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 55 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: ALTO-300 oral (PO) tablet; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Culver City, California • Sacramento, California • Santee, California + 8 more

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Major Depressive Disorder
Interventions: Acute Stressors; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 30 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Stress, Anxiety, Depression
Interventions: VR Mindfulness Meditation Program; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Surgical Stress Response, Stress Physiological, Stress Physiology, Stress Psychological, Breathing Techniques, Breathing Exercises, Hypothalamic Pituitary Adrenal, Relaxation, Relaxation Therapy, Cortisol, Postoperative Pain, Postoperative Anxiety, Postoperative Depression, Quality of Recovery (QoR-15)
Interventions: A 5-minute Asynchronous Breathwork Intervention, A 5-minute Asynchronous Card Game Video; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 65 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Depression, Depressive Symptoms
Interventions: Meru Health Ascend Program; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 40 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Depressive Disorder, Major
Interventions: Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Beverly Hills, California • Burbank, California • Encino, California + 19 more

Conditions: Depression, Insomnia
Interventions: Cognitive Behavioral Therapy for insomnia and depression; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 12 Years to 20 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Berkeley, California • Portland, Oregon

Conditions: Cardiac Surgery, Older Adults, Depression, Anxiety
Interventions: Behavioral activation, Medication optimzation, Care as usual; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Treatment-resistant Depression
Interventions: Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 10
States / cities: Birmingham, Alabama • Orange, California • San Rafael, California + 7 more

Search by objective public record fields.

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

FACE-PC: Family-Centered Care for Older Adults With Depression and Chronic Medical Conditions in Primary Care

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Computerized Cognitive Training in Young Adults With Depression

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Pilot Decentralized Trial

Study of Physical and Mental Health of Older Patients With Newly Diagnosed Cancer

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Treating Alcohol Use In Older Adults With Depression

Linking Affective Dynamics in Response to Daily Stress to Peripheral Vascular Function in Working Age Adults

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Trial to Test Effectiveness of Depression Intervention for Mistreated Older Adults

ALTO-300 in Depression

Psilocybin for Major Depressive Disorder (MDD)

Stress and the Sympathetic Nervous System in Adults With Depression

Assessing the Impact of VR-Based Observational Mindfulness Meditation on Stress Reduction in Adults

Feasibility of Breathwork Intervention With Older Adults After Knee Surgery

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Meru Health Ascend Mobile Intervention for Depression in Middle Aged and Older Adults

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Young Adult and Teen Sleep Study

Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression